Step therapy still gatekeeps CGRP. Your symptom log is the appeal.
When an insurer denies a CGRP preventive for missing prior-therapy documentation, the appeal turns on evidence you can only build across weeks, not remember in a portal.
The letter comes with a code and a sentence
The denial fits in one line: not medically necessary, prior therapies not adequately documented. You have already been through the older preventives. You remember the months of nausea on the beta-blocker and the fog that made the topiramate unlivable. Your insurer does not remember any of it, because remembering was never their job. It was supposed to be in your chart, and most of it never made it there.
Something in the news pulls this conversation back to the surface on a regular cycle, a policy update or a study or a coverage decision that reminds everyone the question is still open. The pattern underneath has not moved: coverage for the CGRP class still runs through a paperwork gate, and the paperwork is yours to produce.
The gate is documentation, not diagnosis
The thing that gets a CGRP preventive denied is rarely a dispute about whether you have migraine. It is the documentation gap. Step therapy asks you to prove you tried and failed older, cheaper drugs first, and the proof standard is a written record of what you took, for how long, and exactly how it failed. Intolerance counts. Inadequate response counts. But only if someone wrote it down at the time.
Most people cannot reconstruct that record from memory once the denial arrives. The dates blur. The side effects that ended a trial six months ago read as vague when you paraphrase them under deadline. An appeal built on "I think it was around spring" loses to an appeal built on entries with dates on them.
What the guidelines say versus what the plan requires
Headache specialists have moved. Professional guidance from the American Headache Society now supports CGRP-targeted therapies as a first-line preventive option rather than a last resort held behind two prior failures, AHS position statement titled 'Calcitonin gene-related peptide-targeting therapies are a first-line option for migraine prevention,' published 2024 in Headache journal. ([source](https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14692)). That is the clinical consensus your neurologist is likely working from.
The coverage rules did not update in lockstep. Many plans still encode a step-therapy or prior-authorization requirement on the class, so the gap a patient falls into is the space between what the specialists recommend and what the formulary was written to allow. Your appeal is, functionally, the argument that closes that gap for your case. It is stronger when your neurologist's letter is backed by a symptom record that shows the older drugs actually failed you.
The appeal, walked through
Picture the second submission after a denial. Your neurologist writes the medical-necessity letter. What makes that letter land is not its adjectives, it is its attachments. A continuous record shows the propranolol trial ran eleven weeks and your logged attack frequency did not drop. It shows the topiramate weeks marked by cognitive fog dense enough that you stopped tracking mid-sentence some days. It shows the postdrome tail after each attack: the residual photophobia, the neck stiffness, the 48 hours you were not functional but were also not "in a headache," which is exactly the disability a same-day-only log erases.
That last part matters more than people expect. Plans underweight migraine burden because they count headache hours. The after-phase is where a lot of the lost days actually live, and a timeline that captures it makes the case for necessity that a headache-only diary cannot.
What the denial cites
What a dated symptom timeline answers
Prior therapies not documented
Drug name, start and stop dates, weeks on it
No evidence of inadequate response
Attack frequency logged before and during each trial
The four lines most often carrying a CGRP step-therapy denial, and the record each one asks for.
What this changes, and what it does not
None of this fixes the policy. A better log will not delete a step-therapy requirement, and we are not going to pretend it might. What it changes is the strength of the response you put back in front of the reviewer, and the fraction of that work you have to do from memory at the worst possible time.
We built Postdrome around a continuous symptom timeline for a reason adjacent to this one: the after-phase gets dropped by tools that close the entry when the headache ends, and it is often the part a clinician or a reviewer most needs to see. The record lives on your device and exports as a PDF you can hand your neurologist for the appeal packet. It is documentation, kept as you go, so it exists before the denial does.
Do not stop a preventive to strengthen an appeal
A denial is a coverage decision, not a medical one. Discontinuing or changing a preventive to build a paper trail is a clinical decision that belongs with your prescriber. Document what happened; do not engineer a failure.
Keep the record before you need it. See how the continuous timeline exports for your appeal.
Postdrome keeps one continuous symptom timeline, including the postdrome after-phase most trackers drop when the headache ends. It runs on-device, and the record exports as a PDF your neurologist can attach to a prior-authorization appeal. Lifetime pricing, stated up front, no subscription.
